Abstract
Trk inhibition led to durable responses in 3/4 patients with NTRK fusion+ thyroid cancer including a novel ETV6-NTRK2 fusion.
Cite
CITATION STYLE
APA
Park, J. C., Ashok, A., Liu, C., & Kang, H. (2022). Real-World Experience of NTRK Fusion–Positive Thyroid Cancer. JCO Precision Oncology, (6). https://doi.org/10.1200/po.21.00442
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free